4251-58-5Relevant academic research and scientific papers
SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF
-
, (2020/02/14)
The present application relates to novel substituted N-arylethyl-2-arylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use there
Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Beck, Hartmut,Thaler, Tobias,Meibom, Daniel,Meininghaus, Mark,J?ri?en, Hannah,Dietz, Lisa,Terjung, Carsten,Bairlein, Michaela,Von Bühler, Clemens-Jeremias,Anlauf, Sonja,Fürstner, Chantal,Stellfeld, Timo,Schneider, Dirk,Gericke, Kersten M.,Buyck, Thomas,Lovis, Kai,Münster, Uwe,Anlahr, Johanna,Kersten, Elisabeth,Levilain, Guillaume,Marossek, Virginia,Kast, Raimund
, p. 11639 - 11662 (2020/11/26)
Idiopathic pulmonary fibrosis (IPF) is a rare and devastating chronic lung disease of unknown etiology. Despite the approved treatment options nintedanib and pirfenidone, the medical need for a safe and well-tolerated antifibrotic treatment of IPF remains
